Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8926947	COVIS	Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents	Mar, 2020 (4 years ago)
US7553479	COVIS	Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof	Mar, 2020 (4 years ago)
US7871597	COVIS	Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents	Mar, 2020 (4 years ago)
US6599498	COVIS	Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives	Jun, 2023 (9 months ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501158	COVIS	Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents	Mar, 2020 (4 years ago)
US8591864	COVIS	Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents	Mar, 2020 (4 years ago)

Feraheme is owned by Covis.

Feraheme contains Ferumoxytol.

Feraheme has a total of 6 drug patents out of which 6 drug patents have expired.

Expired drug patents of Feraheme are:

Feraheme was authorised for market use on 30 June, 2009.

Feraheme is available in solution;intravenous dosage forms.

Feraheme can be used as method of treating patients needing an iron supplement.

The generics of Feraheme are possible to be released after 30 June, 2023.

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 30, 2012
New Indication(I-767)	Feb 02, 2021

Market Authorisation Date: 30 June, 2009

Treatment: Method of treating patients needing an iron supplement

Dosage: SOLUTION;INTRAVENOUS

Feraheme patents expiration